This company develops non-addictive pain therapies to provide alternatives to opioids. They are also creating treatments for opioid addiction, offering healthcare professionals new tools to combat the opioid crisis.
Funding
$8.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current opioid medications used to treat moderate to severe pain carry significant risks, including addiction, respiratory depression, constipation, and potential for fatal overdose. These side effects limit their use and create a substantial unmet need for safer and non-addictive alternatives.
Solution
Phoenix PharmaLabs is developing a portfolio of novel analgesics with unique opioid receptor characteristics designed to provide potent pain relief without the euphoric "high" that leads to abuse and addiction. Their lead candidate, PPL-138, is a Nociceptin compound demonstrating robust analgesic potency, long duration of action, and a lack of typical opioid side effects in preclinical studies. PPL-138 and other compounds in development stimulate opioid receptors in a balanced manner, avoiding excessive dopamine release and minimizing the risk of addiction. Phoenix PharmaLabs' drugs offer a safer alternative for managing acute and chronic pain, as well as potential treatments for addiction and PTSD.
Target Audience
The primary target audience includes individuals suffering from moderate to severe acute and chronic pain, as well as those seeking treatment for opioid addiction and PTSD.
Features
- PPL-138: >100x the potency of morphine in preclinical studies
- Long duration of action (>24 hours for PPL-138)
- Reduced risk of abuse/addiction due to lack of euphoria
- No physical dependence or withdrawal symptoms observed
- Low risk of respiratory depression and overdose
- Minimal constipation compared to traditional opioids
- PPL-103: Binds strongly to Mu, Kappa, and Delta receptors, partially stimulating them in a balanced manner
- PPL-138: Binds to NOP and mu receptors, partially stimulating them to block excessive dopamine release